# A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

> **NCT07700056** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Pruritus of Unknown Origin

## Interventions

- **DRUG:** Remibrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07700056
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-24
- **Primary completion:** 2029-12-19
- **Final completion:** 2030-04-15
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700056, "A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*